@MartinShkreli You sound like a company you'd short. "There's this one example that you probably can't understand but...."

@bombtech25 you have to learn the space. it is not easy. took me a long time.

@MartinShkreli What a giant rent-seeking scam the whole pharma business is.

@Adrian_Bisson yeah you're right. scientists love working for free. especially manufacturing plant people too.

@MartinShkreli Who pays that huge millions amount of $ per treatment? Insurance? Government? Patients?

@EmuConspiracy certainly not the patients lol

@MartinShkreli I bought some just based on your recommendation and refuse to do any research beyond that.

@MartinShkreli Comparative Pros for TA-ERT vs Naglazyme: 1. (Likely) bigger potential patient pool. Cons: 1. Harder delivery slowing uptake/penetration. Nag is IV. 2. Fixed dose vs. weight based. Nag inflates with heavier patients. 3. Diagnosis and treatment window. IIIB skews younger.

@MartinShkreli Literally how alexion built a small empire!

@MartinShkreli Im curious but Im not a Shkreli level researcher. As an expert I just take your word for it

@MartinShkreli just start that ETF already and we are all in charge .69% fee

@MartinShkreli Exactly this. Qalsody population was even lower if I remember correctly

@MartinShkreli The bots replying to this are out of control.

@MartinShkreli Hey Martin, do you have anything else on your radar?

@MartinShkreli Are we running spaces today

@MartinShkreli Check this guy working on Sunday

@MartinShkreli Agreed

@MartinShkreli #doctoreadful 👆👆 This analysis is so accurate📈📈

@MartinShkreli #soma_paint26 🖕🖕 This guy has great judgment.👍📈

@MartinShkreli #oakenlove__XD 👆👆👆 This guy is pretty accurat📈📈📈

@MartinShkreli I'm shorting $SPRB if Trump says the drug is over priced. I'm going to keep an close eye if it dips below $50